<DOC>
	<DOC>NCT01600716</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of OnabotulinumtoxinA (BOTOXÂ®) for the treatment of urinary incontinence due to NDO in non-catheterizing patients with MS.</brief_summary>
	<brief_title>Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder, Neurogenic</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>At least 3 episodes of urinary incontinence over a 3day period History of Multiple Sclerosis (MS) Urinary incontinence not adequately controlled by anticholinergic medication Current use of intermittent catheter or indwelling catheter to manage urinary incontinence Previous or current botulinum toxin therapy of any serotype for any urological condition Previous or current botulinum toxin therapy of any serotype for any nonurological condition within the last 12 weeks Diagnosis of myasthenia gravis, EatonLambert Syndrome, or Amyotrophic Lateral Sclerosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>